Literature DB >> 10861794

Broad specificity of GDNF family receptors GFRalpha1 and GFRalpha2 for GDNF and NTN in neurons and transfected cells.

L C Wang1, A Shih, J Hongo, B Devaux, M Hynes.   

Abstract

The glial cell line-derived neurotrophic factor (GDNF) family of ligands binds to lipid anchored proteins termed GDNF family receptor (GFR)alphas, and then activates the RET receptor tyrosine kinase, by ligand GFRalpha. The binding of soluble GFRalphas to transfected cells suggested that different GFRalphas were dedicated to particular ligands, with GDNF acting primarily or entirely through GFRalpha1, and neurturin (NTN), through GFRalpha2. More recent evidence has suggested the possibility of cross-talk between these ligands and the two receptors. We examined here whether crosstalk between the GDNF ligands and the GFRalphas is biologically relevant, using midbrain dopaminergic, and parasympathetic, submandibular gland neurons. By biochemical and genetic addition and/or deletion of GFRalpha1 and 2, we show that in both neuronal cell types, robust biological activities of GDNF or NTN can be mediated by either GFRalpha1 or GFRalpha2, although GDNF is slightly more potent in dopaminergic (DA) neurons which normally express GFRalpha1, and NTN in submandibular neurons which normally express GFRalpha2. Throughout the body, GDNF and NTN are likely to have important biological actions on both GFRalpha1- and GFRalpha2-expressing cells. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861794     DOI: 10.1002/1097-4547(20000701)61:1<1::AID-JNR1>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  6 in total

1.  Future of cell and gene therapies for Parkinson's disease.

Authors:  Ole Isacson; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

2.  Glial cell line-derived neurotrophic factor and neurturin inhibit neurite outgrowth and activate RhoA through GFR alpha 2b, an alternatively spliced isoform of GFR alpha 2.

Authors:  Li Foong Yoong; Heng-Phon Too
Journal:  J Neurosci       Date:  2007-05-23       Impact factor: 6.167

Review 3.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

4.  Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion.

Authors:  David Reyes-Corona; Nallely Vázquez-Hernández; Lourdes Escobedo; Carlos E Orozco-Barrios; Jose Ayala-Davila; Mario Gil Moreno; Miriam E Amaro-Lara; Yazmin M Flores-Martinez; Armando J Espadas-Alvarez; Manuel A Fernandez-Parrilla; Juan A Gonzalez-Barrios; M E Gutierrez-Castillo; Ignacio González-Burgos; Daniel Martinez-Fong
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

Review 5.  Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease.

Authors:  Arun Kumar Mahato; Yulia A Sidorova
Journal:  Cell Tissue Res       Date:  2020-06-17       Impact factor: 5.249

Review 6.  Improving therapeutic potential of GDNF family ligands.

Authors:  Pia Runeberg-Roos; Richard D Penn
Journal:  Cell Tissue Res       Date:  2020-07-28       Impact factor: 5.249

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.